People with leukemia and their oncologists have vastly different perceptions of prognosis

October 24, 2017, American Society of Clinical Oncology

A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure. These findings will be presented at the upcoming 2017 Palliative and Supportive Care in Oncology Symposium in San Diego, California.

"Patients with AML face very challenging treatment decisions that are often placed upon them within days after being diagnosed," said senior study author Areej El-Jawahri, MD, assistant professor of medicine at Massachusetts General Hospital in Boston, MA. "Because they face a grave decision, they need to understand what the risks of treatment are versus the possibility of a cure."

About the Study

The researchers enrolled 50 patients who were receiving intensive care for AML (which usually meant hospitalization for 4 to 6 weeks) and 50 patients who were receiving non-intensive care (often given as outpatient treatment). The median patient age was 71 years, 92% were white, more than 50% had a college education, and most were from higher income brackets.

Within three days after starting treatment, both the patients and their physicians were given a questionnaire to assess how they perceived the likelihood of dying from the treatment. One month later, they completed a follow-up questionnaire to assess perceptions of prognosis. Within that timeframe, most patients received laboratory results that more definitively established the type and stage of cancer.

Key Findings

Regardless of whether they received intensive or non-intensive care, 63% of patients thought it was somewhat likely they would die due to treatment, and 28% thought it was extremely likely they would die. In contrast, 80% of the treating oncologists thought it was very unlikely that their patients would die due to treatment.

One month later, nearly all (90%) of patients thought it was somewhat or very likely they would be cured of their AML. In contrast, 74% of their oncologists thought it was unlikely or very unlikely that their patients would be cured. The gap between patient and doctor perceptions was most striking for patients receiving non-intensive therapy, with 44% of patients believing they would very likely be cured, while none of their oncologists thought this was very likely.

"There were several very important factors we were not able to capture in our study, including what was actually discussed between patients and their oncologists, and whether patients simply misunderstood or misheard the information conveyed to them," said Dr. El-Jawahri. "Perhaps most importantly, we did not audio-record the discussions between the patients and their physicians, which could provide additional details regarding barriers to accurate prognostic understanding in these conversations."

Prior to this study, the authors had looked at similar perceptions in people with lung, colorectal, and other cancers, as well as in people with blood cancers receiving transplantation. The gaps in perception of treatment risk and cure for patients as compared to their physicians were not as large in those diseases as in AML. The researchers attribute this to higher levels of distress seen in people with AML due to the urgency of their treatment decisions.

Next Steps

The researchers have found that early consideration of palliative care in a plan for patients with solid tumors improves patients' understanding of the prognosis. They hope to implement a similar study in patients with leukemia.

"Clearly there are important communication gaps between oncologists and their patients," said Dr. El-Jawahri. "We need to find ways to help physicians do a better job of communicating with their patients, especially in diseases like AML where stress levels are remarkably high."

Explore further: New referral pathway cuts palliative radiotherapy wait

More information: abstracts.asco.org/200/AbstView_200_197735.html

Related Stories

New referral pathway cuts palliative radiotherapy wait

September 7, 2017
(HealthDay)—Use of an advanced practice radiation therapist (APRT) may help reduce radiotherapy waiting times for palliative patients, according to a study published Aug. 29 in the Journal of Medical Radiation Sciences.

Why fewer blood cancer patients receive hospice care

May 22, 2017
Research has shown that patients with blood cancers are less likely to enroll in hospice care than patients with solid cancers, and the findings from a national survey suggest that concerns about the adequacy of hospice may ...

Heart failure patients, clinicians have differing perceptions of risk level

August 16, 2017
Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death while few of those patients considered themselves to be at high risk, ...

Palliative care helpful for cancer patients receiving bone marrow transplants

November 22, 2016
Integrating palliative care into the treatment of patients undergoing hematopoietic stem cell transplantation (HCT) - commonly known as bone marrow transplantation - for cancers like leukemia and lymphoma can improve their ...

Older cancer patients heavily use health care services

September 2, 2015
(HealthDay)—Older patients with acute myeloid leukemia (AML) are intense users of health care services and rarely use palliative care and hospice services, according to a study published in the August issue of Cancer.

Choosing to die at home does not hasten death for patients with terminal cancer

March 28, 2016
A large study from Japan found that cancer patients who died at home tended to live longer than those who died in hospitals. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings ...

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.